At Trove Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and undertreated respiratory conditions are managed. We are a privately held, clinical-stage, biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins.

Trove is developing a series of recombinant human secretoglobins for a range of orphan and more commonplace respiratory diseases impacting people from infancy through adulthood.

Trove Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human SCGB1A1 protein (rhSCGB1A1), which has potential clinical applications in a wide range of respiratory diseases.Learn More
Trove Therapeutics holds specialized expertise required for the creation, development and commercialization of the secretoglobin family of proteins.Learn More
Trove’s experienced biopharmaceutical executives and professionals, the Management Team and Board of Directors, have the technical and business acumen to advance our development programs from the research bench to clinical practice.Learn More


Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native SCGB1A1 protein in patients. We are developing a pharmaceutical therapy to replace SCGB1A1 with the synthetic version (rhSCGB1A1) in respiratory diseases characterized by inflammation and pre-existing SCGB1A1 deficiency.


Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring SCGB1A1 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. rhSCGB1A1 has the potential to modify, or to help resolve inflamed airways in a wide range of respiratory conditions such as asthma, chronic sinusitis, COPD and pulmonary fibrosis, unlike many treatments that provide symptomatic treatment only. We are developing a platform of pharmaceutical therapies to replace native SCGB1A1 with rhSCGB1A1 in an effort to improve respiratory conditions characterized by inflammation and SCGB1A1 deficiency.

Trove Therapeutics, Inc. is a Delaware biotechnology corporation headquartered in Rockville, Maryland.

The Statistics Are Truly Overwhelming

Our goal is to improve long-term health outcomes and in doing so, potentially reduce healthcare costs.

Americans with Recurrent Acute Sinusitis
Number of Lives COPD Claims Annually
Estimated Sufferers from Asthma
Americans Affected by Pulmonary Fibrosis